{"id":55118,"date":"2026-01-22T10:57:06","date_gmt":"2026-01-22T02:57:06","guid":{"rendered":"https:\/\/flcube.com\/?p=55118"},"modified":"2026-01-22T10:57:08","modified_gmt":"2026-01-22T02:57:08","slug":"lillys-sofetabart-wins-fda-breakthrough-status-for-platinum-resistant-ovarian-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55118","title":{"rendered":"Lilly\u2019s Sofetabart Wins FDA Breakthrough Status for Platinum\u2011Resistant Ovarian Cancer"},"content":{"rendered":"\n<p><strong>Eli Lilly and Company<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE:\u202fLLY<\/a>) announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has granted <strong>Breakthrough Therapy Designation (BTD)<\/strong> to <strong>sofetabart mipitecan (LY4170156)<\/strong>, a <strong>folate receptor alpha (FR\u03b1) antibody\u2011drug conjugate (ADC)<\/strong>, for <strong>platinum\u2011resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer<\/strong> in patients previously treated with bevacizumab and mirvetuximab soravtansine.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Eli Lilly and Company (NYSE:\u202fLLY)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Sofetabart mipitecan (LY4170156)<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>Breakthrough Therapy Designation (BTD)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>U.S. FDA<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Platinum\u2011resistant ovarian\/fallopian tube\/primary peritoneal cancer (post\u2011bevacizumab + mirvetuximab)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>FR\u03b1 ADC with proprietary linker + exatecan payload<\/td><\/tr><tr><td><strong>Basis<\/strong><\/td><td>Phase\u202f1 responses at all dose levels and FR\u03b1 expression levels, including post\u2011mirvetuximab progression<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Low ILD, peripheral neuropathy, alopecia; no ocular toxicity<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Phase\u202f3 FRAmework\u201101 study (NCT07213804) \u2013 monotherapy in PROC, combo with bevacizumab in PSOC<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-differentiation\">Drug Profile &amp; Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>FR\u03b1\u2011targeting ADC<\/strong> delivering <strong>exatecan payload<\/strong>, a <strong>topoisomerase I inhibitor<\/strong> with high potency<\/li>\n\n\n\n<li><strong>Proprietary Linker:<\/strong> Designed for <strong>stable circulation<\/strong> and <strong>controlled tumor release<\/strong>, minimizing off\u2011target toxicity<\/li>\n\n\n\n<li><strong>Key Advantage:<\/strong> Demonstrates <strong>activity across all FR\u03b1 expression levels<\/strong>, including <strong>low\u2011expressors<\/strong>, and <strong>post\u2011mirvetuximab<\/strong> patients, suggesting <strong>non\u2011cross\u2011resistance<\/strong><\/li>\n\n\n\n<li><strong>Safety:<\/strong> <strong>Favorable tolerability<\/strong> with <strong>low rates of ILD (&lt;2%), peripheral neuropathy (&lt;5%), alopecia (&lt;3%)<\/strong>, and <strong>no ocular toxicity<\/strong> \u2013 a key differentiator vs. mirvetuximab<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-amp-development-path\">Clinical Evidence &amp; Development Path<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study<\/th><th>Design<\/th><th>Key Findings<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase\u202f1<\/strong><\/td><td>Dose\u2011escalation\/expansion<\/td><td>Responses at all dose levels; activity in low FR\u03b1 and post\u2011mirvetuximab patients<\/td><\/tr><tr><td><strong>Phase\u202f3 (FRAmework\u201101)<\/strong><\/td><td>Monotherapy (PROC) + combo with bevacizumab (PSOC)<\/td><td>Initiated 2026; primary endpoints: PFS, ORR<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>PFS by RECIST 1.1 (PROC), OS (exploratory)<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase\u202f3 Launch:<\/strong> <strong>NCT07213804<\/strong> initiated in <strong>Q1\u202f2026<\/strong>, targeting <strong>enrollment completion by Q4\u202f2027<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Platinum\u2011Resistant Ovarian Cancer (PROC)<\/th><th>Global Ovarian Cancer Market<\/th><\/tr><\/thead><tbody><tr><td><strong>Annual Incidence (2026E)<\/strong><\/td><td>45,000 (US)<\/td><td>300,000<\/td><\/tr><tr><td><strong>FR\u03b1\u2011Positive (\u22651%)<\/strong><\/td><td>35\u201140% of cases<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Post\u2011Mirvetuximab Eligible<\/strong><\/td><td>60% of FR\u03b1\u2011positive PROC<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>Chemo (liposomal doxorubicin), PARP inhibitors (limited)<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Annual Cost (Est.)<\/strong><\/td><td>$180,000\u2011220,000<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Sofetabart Peak Share (2032E)<\/strong><\/td><td>25%<\/td><td>8%<\/td><\/tr><tr><td><strong>Peak Revenue (2032E)<\/strong><\/td><td>$180\u202fmillion (PROC)<\/td><td>$420\u202fmillion (global ovarian)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mirvetuximab soravtansine<\/strong> (Elahere, ImmunoGen\/AbbVie) \u2013 First\u2011in\u2011class FR\u03b1 ADC, approved for FR\u03b1\u2011high PROC; <strong>limited activity post\u2011progression<\/strong><\/li>\n\n\n\n<li><strong>PARP inhibitors<\/strong> (olaparib, niraparib) \u2013 Maintenance therapy, not for platinum\u2011resistant disease<\/li>\n\n\n\n<li><strong>Chemotherapy<\/strong> \u2013 Standard of care, <strong>poor outcomes<\/strong> (ORR\u202f&lt;\u202f15%)<\/li>\n\n\n\n<li><strong>Sofetabart<\/strong> \u2013 <strong>Potential best\u2011in\u2011class<\/strong> with <strong>broader FR\u03b1 coverage<\/strong> and <strong>superior safety profile<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> Lilly\u2019s <strong>Indianapolis biologics facility<\/strong> (capacity 20,000\u202fL) will produce sofetabart; <strong>FDA inspection completed<\/strong> 2025<\/li>\n\n\n\n<li><strong>Commercial Readiness:<\/strong> <strong>800\u2011person US oncology sales force<\/strong> already detailing <strong>Verzenio<\/strong> and <strong>Retevmo<\/strong>; <strong>cross\u2011detailing capability<\/strong> for sofetabart upon approval<\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> Lilly plans <strong>EU MAA filing<\/strong> in <strong>2027<\/strong> and <strong>Japan filing<\/strong> in <strong>2028<\/strong>, leveraging <strong>Phase\u202f3 data<\/strong><\/li>\n\n\n\n<li><strong>Next\u2011Generation Pipeline:<\/strong> Success validates <strong>exatecan payload platform<\/strong> for <strong>other ADC targets<\/strong> (e.g., <strong>HER3, B7\u2011H4<\/strong>)<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Phase\u202f3 trial outcomes, regulatory approvals, and commercial forecasts for sofetabart mipitecan. Actual results may differ due to competitive responses, clinical trial risks, and market access dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company (NYSE:\u202fLLY) announced that the U.S. Food and Drug Administration (FDA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,34,16,199,911],"class_list":["post-55118","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-breakthrough-therapy","tag-cancer","tag-eli-lilly","tag-nyse-lly"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lilly\u2019s Sofetabart Wins FDA Breakthrough Status for Platinum\u2011Resistant Ovarian Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company (NYSE:\u202fLLY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to sofetabart mipitecan (LY4170156), a folate receptor alpha (FR\u03b1) antibody\u2011drug conjugate (ADC), for platinum\u2011resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients previously treated with bevacizumab and mirvetuximab soravtansine.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55118\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lilly\u2019s Sofetabart Wins FDA Breakthrough Status for Platinum\u2011Resistant Ovarian Cancer\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly and Company (NYSE:\u202fLLY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to sofetabart mipitecan (LY4170156), a folate receptor alpha (FR\u03b1) antibody\u2011drug conjugate (ADC), for platinum\u2011resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients previously treated with bevacizumab and mirvetuximab soravtansine.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55118\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-22T02:57:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T02:57:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55118#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55118\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lilly\u2019s Sofetabart Wins FDA Breakthrough Status for Platinum\u2011Resistant Ovarian Cancer\",\"datePublished\":\"2026-01-22T02:57:06+00:00\",\"dateModified\":\"2026-01-22T02:57:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55118\"},\"wordCount\":496,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Breakthrough therapy\",\"Cancer\",\"Eli Lilly\",\"NYSE: LLY\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55118#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55118\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55118\",\"name\":\"Lilly\u2019s Sofetabart Wins FDA Breakthrough Status for Platinum\u2011Resistant Ovarian Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-22T02:57:06+00:00\",\"dateModified\":\"2026-01-22T02:57:08+00:00\",\"description\":\"Eli Lilly and Company (NYSE:\u202fLLY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to sofetabart mipitecan (LY4170156), a folate receptor alpha (FR\u03b1) antibody\u2011drug conjugate (ADC), for platinum\u2011resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients previously treated with bevacizumab and mirvetuximab soravtansine.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55118#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55118\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55118#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lilly\u2019s Sofetabart Wins FDA Breakthrough Status for Platinum\u2011Resistant Ovarian Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lilly\u2019s Sofetabart Wins FDA Breakthrough Status for Platinum\u2011Resistant Ovarian Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly and Company (NYSE:\u202fLLY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to sofetabart mipitecan (LY4170156), a folate receptor alpha (FR\u03b1) antibody\u2011drug conjugate (ADC), for platinum\u2011resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients previously treated with bevacizumab and mirvetuximab soravtansine.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55118","og_locale":"en_US","og_type":"article","og_title":"Lilly\u2019s Sofetabart Wins FDA Breakthrough Status for Platinum\u2011Resistant Ovarian Cancer","og_description":"Eli Lilly and Company (NYSE:\u202fLLY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to sofetabart mipitecan (LY4170156), a folate receptor alpha (FR\u03b1) antibody\u2011drug conjugate (ADC), for platinum\u2011resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients previously treated with bevacizumab and mirvetuximab soravtansine.","og_url":"https:\/\/flcube.com\/?p=55118","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-22T02:57:06+00:00","article_modified_time":"2026-01-22T02:57:08+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55118#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55118"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lilly\u2019s Sofetabart Wins FDA Breakthrough Status for Platinum\u2011Resistant Ovarian Cancer","datePublished":"2026-01-22T02:57:06+00:00","dateModified":"2026-01-22T02:57:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55118"},"wordCount":496,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Breakthrough therapy","Cancer","Eli Lilly","NYSE: LLY"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55118#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55118","url":"https:\/\/flcube.com\/?p=55118","name":"Lilly\u2019s Sofetabart Wins FDA Breakthrough Status for Platinum\u2011Resistant Ovarian Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-22T02:57:06+00:00","dateModified":"2026-01-22T02:57:08+00:00","description":"Eli Lilly and Company (NYSE:\u202fLLY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to sofetabart mipitecan (LY4170156), a folate receptor alpha (FR\u03b1) antibody\u2011drug conjugate (ADC), for platinum\u2011resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients previously treated with bevacizumab and mirvetuximab soravtansine.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55118#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55118"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55118#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lilly\u2019s Sofetabart Wins FDA Breakthrough Status for Platinum\u2011Resistant Ovarian Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55118","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55118"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55118\/revisions"}],"predecessor-version":[{"id":55119,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55118\/revisions\/55119"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55118"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}